Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zealand Pharma
Biotech
Boehringer links dual agonist to 16.6% weight loss in phase 3
While the result fell short of the bar set by existing drugs, targeting glucagon could make survodutide better at cutting cardiometabolic risk.
Nick Paul Taylor
Apr 28, 2026 4:00am
Zealand's Zupreme serves up to 10.7% mean weight loss
Mar 5, 2026 4:44pm
How Zealand CSO aims to create a 'generational biotech leader'
Dec 12, 2025 1:00pm
Zealand pens $2.5B cardiometabolic collab with Chinese biotech
Dec 11, 2025 5:45am
Zealand pumps brakes on development of dual GLP-1/GLP-2 agonist
Nov 13, 2025 9:52am
What’s next for Roche’s expensive obesity pipeline?
Sep 19, 2025 10:16am
